This guidance document has been produced to provide guidance to organisations completing the Emergency Preparedness, Resilience and Response (EPRR) annual assurance process.
In April 2018, updated interim guidance was issued in response to changes in available IV immunoglobulin products in the NHS. Based on testing carried out by NIBSC of 7 other IV immunoglobulin products to determine if they have similar levels
This document on the flu vaccination and vaccination programme includes information on: what flu is the flu vaccine dosage administering the vaccine advice on vaccinating children with an egg allergy further resources
Updated Heatwave Plan for England which aims to prepare for, alert people to, and prevent, the major avoidable effects on health during periods of severe heat in England. It recommends a series of steps to reduce the risks to health
University of Manchester evaluation of the Saving Babies Lives Care Bundle that demonstartes clinical improvements such as better monitoring of a baby’s growth and movement in pregnancy, as well as better monitoring in labour, led to maternity staff helping to
This handbook contains information, indications and guidance for the use of immunoglobulin preparations for each individual disease. Immunoglobulins are concentrated antibody preparations which provide immediate short-term protection against disease for individuals at high risk of severe disease or serious complications from
Framework that sets out the essential skills and knowledge necessary for staff with a role as a first point of contact for adults presenting with undiagnosed musculoskeletal conditions. It is relevant to different types of service provision and settings, and
The average number of heat-related deaths in the UK is expected to more than triple to 7,000 a year by the 2050s. Older people are particularly vulnerable and suffer increased fatalities from cardiac and respiratory disease during heatwaves. As the
Evidence-based recommendations on ocrelizumab (Ocrevus) for treating relapsing–remitting multiple sclerosis in adults. Ocrelizumab is recommended as an option for treating relapsing–remitting multiple sclerosis in adults with active disease defined by clinical or imaging features, only if: alemtuzumab is contraindicated or
Evidence-based recommendations on transaxial interbody lumbosacral fusion for low back pain in adults. This involves removing a damaged disc through a small cut at the base of the spine, and replacing it with an artificial implant. This guidance replaces NICE interventional
Evidence-based recommendations on superior capsular augmentation for massive rotator cuff tears in adults. This involves using a graft to stabilise the shoulder joint, reduce pain and improve shoulder function.
Evidence-based recommendations on cenegermin (Oxervate) for treating neurotrophic keratitis in adults.
Evidence-based recommendations on pembrolizumab (Keytruda) for untreated PD-L1-positive metastatic non-small-cell lung cancer in adults. This guidance replaces NICE technology appraisal guidance 447.
This guideline covers diagnosing and managing early and locally advanced breast cancer. It aims to help healthcare professionals offer the right treatments to people, taking into account the person’s individual preferences. NICE has also produced guidelines on advanced breast cancer, familial breast
This quality standard covers assessing if people need help with their medicines and deciding what medicines support is needed to enable people to manage their medicines. It also includes communication between health and social care staff, to ensure people have
These guidelines aim to increase awareness and understanding of CJD and improve social care for people who are affected by it. The guidelines update the previous guidance published in 2003. They reflect the increasing rareness of the disease and the
This booklet is designed to help families, parents and carers of those with a learning disability and autistic people to give feedback, raise concerns and make complaints across education, health and social care.
In this scenario – using a fictional patient, Rob – a sepsis care pathway is examined, comparing a sub-optimal but typical scenario against an ideal pathway. At each stage we have modelled the costs of care, not only financial to the local health
This document explains how remuneration is calculated, depending on how dental practices have entered a prototype agreement. The directions 2016 contain amendments to the statement of financial entitlement to make provision for the community dental services prototypes.
Extending the dental prototype agreement scheme from 1 April 2018 to 31 March 2020. Regulations setting out specific terms and conditions for dental prototype agreements.